Gamini Soori, MD Co-Authors Abstract Chosen for Presentation at San Antonio Breast Cancer Symposium

Clinical Study Focuses on Extended Adjuvant Therapy with Letrozole

Fort Myers, Fla., December 20, 2019 — Medical oncologist Gamini S. Soori, MD, MBA, FACP, FRCP, CPE, who practices in Florida Cancer Specialists (FCS) locations in Cape Coral and Fort Myers, was a co-author of a study evaluating the efficacy of extended endocrine (hormonal) therapy with letrozole in postmenopausal women with hormone-receptor positive (HR+) breast cancer, who have previously completed adjuvant therapy with an aromatase inhibitor. The study was presented and published as an abstract at the prestigious 2019 San Antonio Breast Cancer Symposium (SABCS), a five-day program attended by a broad international audience of academic and private researchers and physicians from over 90 countries.

Gamini Soori MD Headshot PR

Providing five-years of adjuvant endocrine therapy has been shown to reduce breast cancer recurrences in certain types of breast cancer and improve associated mortality. In the study, Dr. Soori and his co-authors sought to determine if extending adjuvant therapy with letrozole for an additional five years would improve disease-free survival (DFS) in patients who had already completed five years of hormonal therapy.

The clinical study included 3966 postmenopausal patients with stage I-III, HR+ breast cancer, who were disease-free after five years of an aromatase inhibitor or tamoxifen; it extended treatment with letrozole for an additional five years in a randomized, double-blind, placebo-controlled trial. In its primary analyses, the study found “the beneficial effect of extended treatment with 5 years of letrozole (L) did not reach statistical significance on disease-free survival (DFS). There was no significant improvement in overall survival (OS) with L, but L did provide a significant improvement in breast-cancer-free interval (BCFI) and distance recurrence (DR).”

Based on data received as of April 30, 2019, updated results from the 10-year-long trial were presented in the SABCS abstract, which concluded, “The effect of extended treatment with 5 years of L on DFS persisted in the updated analyses and reached statistical significance. There was no significant improvement in OS with L, but L continued to provide a significant improvement in BCFI and DR.” Letrozole resulted in 26% decrease in Breast Cancer Free Interval events. Furthermore, there was 29% reduction in distant recurrence.
These improvements are meaningful to our breast cancer patients by reducing the burden of recurrence and distant spread of their breast cancer.

Dr. Gamini Soori contributed to this work as the Principal Investigator of NCI-funded Missouri Valley Cancer Consortium and Clinical professor of Medicine, Creighton University School of Medicine in Omaha, Nebraska.

###

About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com)
Recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award, Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida. In the past 4 years, the majority of new cancer drugs approved for use in the U.S. were studied in clinical trials with Florida Cancer Specialists participation.* Trained in such prestigious medical schools and research institutes as Duke, Stanford, Harvard, Emory, M.D. Anderson, and Memorial Sloan Kettering, our physicians are consistently ranked nationally as Top Doctors by U.S. News & World Report.

Founded in 1984, FCS is one of the largest medical oncology/hematology practices in the United States. With more than 230 physicians, 220 advanced practice registered nurses (APRN) and physician assistants (PA) and nearly 100 locations in our network, we are committed to providing world-class cancer care in community-based settings, close to home.

Florida Cancer Specialists has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research, cutting-edge technologies and advanced treatments, including targeted therapies, genomic-based treatment, and immunotherapy.  Our highest values are embodied by our outstanding team of highly trained and dedicated physicians, clinicians and staff.

Since 2005, Florida Cancer Specialists has been a strategic research site for Sarah Cannon Research Institute, with special focus on early phase research and drug development.

About Sarah Cannon Research Institute
Focused on advancing therapies for patients, Sarah Cannon Research Institute is one of the world’s leading clinical research organizations conducting community-based clinical trials throughout the United States and United Kingdom. A leader in drug development, Sarah Cannon has led more than 400 first-in-human clinical trials since its inception in 1993 and has been a clinical trial leader in the majority of approved cancer therapies over the last 10 years. Additionally, Sarah Cannon offers management, regulatory, and other research support services for drug development and industry sponsors as well as strategic investigator sites through its contract research organization (CRO), Sarah Cannon Development Innovations. For more information, visit SarahCannon.com.

For More Information Contact:
Florida Cancer Specialists & Research Institute
Shelly Glenn, Chief Marketing & Sales Officer
SGlenn@FLCancer.com
(770) 365.6168

Florida Cancer Specialists & Research Institute
Michelle Robey, Director of Marketing & Communications
Michelle.Robey@FLCancer.com
(813) 767-9398